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IL-33 is a known member of the IL-1 cytokine superfamily classically named “atypical” 
due to its diverse functions. The receptor for this cytokine is the ST2 chain (or IL-1RL1), 
part of the IL-1R family, and the accessory chain IL-1R. ST2 can be found as both 
soluble and membrane-bound forms, property that explains, at least in part, its wide 
range of functions. IL-33 has increasingly gained our attention as a potential target to 
modulate immune responses. At the beginning, it was known as one of the participants 
during the development of allergic states and other Th2-mediated responses and it is 
now accepted that IL-33 contributes to Th1-driven pathologies as demonstrated in 
animal models of experimental autoimmune encephalomyelitis (EAE), collagen-induced 
arthritis, and trinitrobenzene sulfonic acid-induced experimental colitis, among others. 
Interestingly, current data are placing IL-33 as a novel regulator of immune tolerance 
by affecting regulatory T cells (Tregs); although the mechanism is not fully understood, 
it seems that dendritic cells and myeloid suppressor-derived cells may be cooperating 
in the generation and/or establishment of IL-33-mediated tolerance. Here, we review 
the most updated literature on IL-33, its role on T cell biology, and its impact in immune 
tolerance.
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introduction
In 2005, IL-33 was first described as a member of the IL-1 family using computational sequence 
analysis, which revealed the existence of a β-trefoil-fold structure in its C-terminal domain, a charac-
teristic feature of IL-1 family members such as IL-1β and IL-18 (1). In the same work, it was also found 
that IL-33 interacts with the IL-1 family receptor ST2, previously described as an orphan receptor 
expressed on Th2 cells and mast cells. When activated with IL-33, ST2 promotes Th2 cell responses 
over Th1 responses (1), and negatively regulates TLR–IL-1R receptor signaling (2).
IL-33 is known as an alarmin because of its high expression in endothelial and epithelial cells 
exposed to tissue damage or pathogen encounter, in addition to its accumulation in the nucleus of those 
cells, similar to other alarmin members of the IL-1 family such as HMGB1 and IL-1α (3). Therefore, 
upon injury or infection, IL-33 is released from the nucleus of endothelial cells to the extracellular 
space where it can signal and activate immune cells, such as mast cells, eosinophils, basophils, natural 
killer cells, and T cells (as many other functions described in this review) (Figure 1) (4).
FiguRe 2 | Model of iL-33 protein, with its two principal domains and functions.
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an N-terminal pro-peptide containing a nuclear localization 
domain (3, 6), which seems to be essential to IL-33 function 
in vivo because specific deletion of this nuclear domain (using 
a knock-in mouse model) results in a systemic, ST2-dependent, 
non-resolving lethal inflammation due to constitutive release of 
IL-33 into the circulation (7).
As other members of the IL-1 family, IL-33 can suffer 
post-translational modifications resulting in two different 
forms: the full-length protein (proIL-33) and the processed 
or “mature” form (mIL-33). mIL-33 is formed after proIL-33 
cleavage in its N-terminal domain, but the cleavage sequence 
is different compared to other members of the IL-1 family, 
such as proIL-1β and IL-18 (8) (Figure 2). In the extracellular 
space, IL-33 binds to its membrane receptor ST2 activating 
the MyD88-dependent pathway, which is involved in cytokine 
secretion, cell activation, and differentiation (9). IL-33 can 
also bind to the soluble form (sST2) of its receptor, which 
corresponds to a decoy receptor that captures IL-33, avoiding 
or blocking intracellular signaling (10). Recently, it has been 
highlighted that the two forms of IL-33 (proIL-33 and mIL-33) 
are biologically active and they can trigger different immune 
responses (11).
The nuclear localization of IL-33 led to study a possible role in 
controlling gene expression, as discussed below.
iL-33 as a Transcription Factor
As mentioned, IL-33 sequence does not contain a clear signal peptide, 
suggesting an (ancestral) intracellular localization. This observation 
suggests that IL-33 has a role as intracellular factor. Based on the 
similarities of IL-33 with other members of the IL-1 cytokine family, 
and the high-mobility group box-1 (HMGB1) protein, Carriere and 
colleagues studied the sequence, molecular, and cellular function 
Human IL-33 is a 30 kDa protein that shares 54% amino acid 
identity with its mouse homolog (5). Along its 270 amino acid 
sequence, we can describe a distinctive C-terminal IL-1-like 
cytokine domain of the IL-1 cytokine family and a central domain 
(1). IL-33 lacks a clear signal peptide, but it is synthesized with 
FiguRe 1 | iL-33 diversity of functions.
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of IL-33. In the first set of experiments, the group confirmed IL-33 
nuclear localization, and interestingly, this location overlapped with 
high concentrations of DNA, suggesting that endogenous IL-33 binds 
to heterochromatin. This observation was confirmed using GFP-
tagged IL-33 constructs, which, in addition, indicated that IL-33 binds 
to mitotic chromatin (12). Sequence and mutagenic experiments 
indicated that the N-terminal section of the protein is necessary for 
nuclear targeting, binding to heterochromatin and mitotic chromo-
somes, specifically the homodomain-like helix–turn–helix segment. 
Making the association that heterochromatin relates with unreachable 
or unexposed DNA, the investigators assayed IL-33 gene expression 
regulatory properties using a luciferase-based reporter system and 
showed that IL-33 acts as a repressor factor (12). In another report, 
it was described that endogenous IL-33 interacts physically with the 
transcription factor NF-κB. By performing co-immunoprecipitation 
experiments and microscopy, the investigators demonstrated that 
IL-33 binds to a free and activated NF-κB. In other words, IL-33 does 
not interact with κB (13). Supporting Carriere’s report, this group 
also found that IL-33 N-terminal sequence interacts with NF-κB, 
reducing its binding to DNA and repressing NF-κB transcription 
factor activity, as shown in EMSA and luciferase-based reporter 
experiments. Altogether, these reports indicate that endogenous 
IL-33 acts as a transcription factor (Figure 1).
A Multifaceted Cytokine
iL-33 and APCs
In addition to the role in the activation of the immune responses, 
IL-33 has also different roles in T cell polarization by modulat-
ing APCs. For example, IL-33 promotes the expansion of APCs, 
principally dendritic cells (DCs), by stimulating the secretion 
of basophils-derived GM-CSF (14). In a different study, Rank 
and colleagues found that DCs express high levels of intracel-
lular ST2, and that the in  vitro treatment of DCs with IL-33 
induces the secretion of IL-6, upregulates the expression levels 
of MHC-II and CD86, and triggers the polarization of naïve 
T cells toward a Th2 phenotype (15). Similarly, Besnard and 
colleagues showed that IL-33 exposure induces the recruitment 
and activation of DCs in the lung, and their posterior migration 
to lymph nodes for antigen presentation in an allergic airway 
inflammation model (16). Alternatively, an indirect role of IL-33 
on DCs was described by Duan and colleagues, who showed that 
IL-33 indirectly modulates intestinal DCs phenotype toward a 
tolerogenic profile given by the expression of CD103+CD11c+ 
(17). Supporting this potential tolerogenic effect, it was recently 
shown that IL-33 promotes IL-2 secretion by DCs, favoring the 
expansion of Foxp3+ Tregs cells (18).
iL-33 and CD4+ T Cells
A lot has been described about the abilities of IL-33 to modulate the 
immune response. One of our particular interests is the capacity 
to direct CD4+ T cells polarization to different phenotypes, with 
the purpose to manipulate immunity under pathogenic conditions, 
favoring a healthy state. In this line, we believe IL-33 is a good 
candidate to exploit, and here we review IL-33 effects on different 
T cells subsets (Table 1).
iL-33 on Th1/Th17
The context in which IL-33 is present influences directly the 
kind of immune response triggered. Thus, in certain cases, IL-33 
can induce a Th1- or Th17-type response (Figure  1). These 
outcomes participate in the development and establishment of 
inflammatory responses that usually relate to diseases, such as 
autoimmunity, or to detrimental inflammatory responses such as 
graft-versus-host disease (GvHD) for the case of transplantation. 
Because of this, to understand the conditions when this cytokine 
would induce an inflammatory response over a tolerogenic 
one, it is essential when considering candidates for therapeutic 
interventions.
We believe that IL-33 versatility has contributed to the 
contradictory studies using animal models. For example, in the 
experimental autoimmune encephalomyelitis (EAE) model, 
some investigators have reported that IL-33 blockade during the 
developing stage of MOG-induced EAE reduces the severity of 
the disease, in part, due to the inhibition of MOG-dependent 
IL-17 and IFN-γ production. Unexpectedly, the treatment with 
exogenous IL-33 increased the severity of the disease by enhancing 
the production of these cytokines. Conversely, the treatment with 
an anti-IL-33 antibody reversed the symptoms and improved the 
state of the mice (19). In contrast with these findings, Jiang and 
colleagues observed an improvement in EAE mice after IL-33 treat-
ment (20). When comparing both works, we identified differences 
that may contribute to obtain such contradictory results as the 
immunization (MOG peptide) site/location, timing, and peptide 
amount. Nevertheless, the kinetics and severity of the disease are 
equal in both cases. In addition, IL-33 treatment differs in both 
works; Li et al. injects the mice every other day, since day 0–18 
with 50 μg/kg; while Jiang’s group treat the mice with 1 μg total 
from day 12 to 20 after immunization. These differences, especially 
in the treatment, can be related to the different results obtained, 
leading us to think that the effect given by IL-33 is time dependent 
and may affect different cell populations in each case. The IL-33 
receptor ST2 can be expressed on astrocytes in the nervous system 
(37); thus, a potential impact of this cytokine on glial cells is very 
likely and may vary with the inflammatory state of them.
Similar to the EAE model, conflicting data are also reported 
for rheumatoid arthritis (RA). For example, some studies indicate 
that IL-33 is prejudicial for this disease because it induces a 
Th17-type response, which aggravates the symptoms (21, 22). In 
collagen-induced arthritis (CIA), it has been described that IL-33 
has similar effects, developing a strong autoimmune response 
mediated by Th17 cells (22). According to these data, the blockade 
of ST2 helps to diminish the severity of CIA through a decrease 
in the production of IFN-γ and IL-17 (21, 23). However, other 
authors state that the role of IL-33 in this specific disease is not 
relevant. For example, Talabot-Ayer and colleagues showed in 
models of CIA and antigen-induced arthritis (AIA) that IL-33 
knock-out mice develop the disease despite the lack of IL-33. 
They conclude that IL-33 does not play an essential role for the 
development of the disease, but it may contribute to the inflam-
matory environment (24).
Other disease linked to IL-33 is asthma. When IL-33 expression 
is deregulated, Th2 cells, mast cells, basophils, and others cells get 
TAbLe 1 | iL-33 effects in T cells.
Cell type experimental model Observations Reference
CD4 Thl/Thl7 EAE IL-33 blockade during MOG-dependent development reduces disease severity by decreasing 
IFN- γ and IL-17
(19)
Treatment with exogenous IL-33 increases disease severity through IFN-γ and IL-17 secretion
αlL-33 treatment improves symptoms
EAE IL-33 treatment improves symptoms (20)
RA, CIA IL-33 induces Th1 and Th17 responses (21–23)
ST2 blockade reduces severity by diminishing IFN-γ and IL-17 production
CIA, AIA Presence of IL-33 did not affect development of the disease (24)
OVA-induced allergic asthma IL-33 induces the secretion of IL-6 and IL-1β from mast cells, promoting Th17 differentiation (25)
CD4 Th2 Experimental atherosclerosis IL-33 upregulates serum levels of Th2 cytokines and enriches for CD4+ST2+ T cells (26)
Innate immunity IL-33 acts on mast cells, basophils, eosinophils, type 2 innate lymphoid cells (ILC2), which 
promotes the secretion of Th2 cytokines, favoring Th2 polarization
(22, 27–29)
CD4 Tregs Chronic colitis Treatment with IL-33 reduces disease symptoms through a decrease on IFN-γ production, 
switching from a Th1 to a Th2 type response
(17, 30, 31)
IL-33 affects directly Tregs in mice
IL-33 expands Tregs Foxp3+ST2+
EAE IL-33-treated mice show an increase in Tregs and M2 macrophages (20)
Atherosclerosis IL-33 prevents the development of atherosclerosis in Apo3−/− mice (26, 32)
IL-33 treatment produces an increment in IL-4, IL-5, and IL-13 production and a decrease in 
IFN-γ levels
IL-33/ST2 axis is involved in the development of the disease
Transplantation Heart-transplanted mice treated with IL-33 show increased graft survival (33)
IL-33 treatment increases the number of CDllb + GRlint MDSC and Tregs, in addition to a  
less IL-17 production and elevated levels of IL-5, IL-13, and IL-10
CD8 IL-33 is up-regulated in CD8+ T cells (34)
ST2 expression is T-bet-dependent
IL-33 plus IL-12 enhance CD8+ T cell effector phenotype
Lymphocytic choriomeningitis 
virus
IFN-γ, ST2, and IL-33 expressions were upregulated after infection (35)
Herpesvirus IL-33 signaling is necessary for an effective CTL response (35)
Tumor Tumor-derived IL-33 inhibits tumor growth and blocks the entrance of tumor-infiltrating 
lymphocytes (TILs)
(36)
Mice-bearing IL-33-secreting tumor have more activated and differentiated CD8+ T cells,  
which is related to T-bet and Eomes expression
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activated triggering the expression of cytokines and chemokines 
that characterizes the disease (38). However, in a model of OVA-
induced allergic asthma, the authors described a predominant 
Th17-type response, which is induced by the activation of ST2/
IL-33 signaling on mast cells. The authors observed that mast cells 
from IL-33-treated mice produced IL-1β and IL-6, collaborating 
with Th17 cells development (25).
These few examples show us the pleiotropic abilities of this 
cytokine, which can direct CD4+ T cells differentiation to Th1 
and Th17, causing and participating in different inflammatory 
states and diseases.
iL-33 on Th2
As mentioned earlier, IL-33 can also modulate Th2 type responses 
(Figure  1) in addition to its effect on Th1 cells. In  vitro and 
in vivo data suggest that IL-33 indirectly promotes Th2 responses 
functioning as a chemoattractant for this type of cells (39, 40). 
Other studies demonstrated that IL-33 could directly act on 
CD4+ST2+ Th2 cells promoting the secretion of IL-4, IL-5, 
and IL-13 (40–42). IL-33 has shown a protective role in the 
ApoE−/− experimental atherosclerosis mice model, increasing 
serum levels of Th2-type cytokines, and enriching ST2+CD4+ 
T cells in lymph nodes (26). These observations indicate that 
IL-33 affects Th2 cell cytokine production in a TCR-independent 
fashion. Moreover, IL-33 promotes Th2-type responses by signal-
ing on other immune cells rather than CD4+ T cells. In this case, 
it has been reported that IL-33 induces mast cells activation, 
maturation, and cytokine production such as IL-5, IL-6, IL-8, and 
IL-13 (22, 27, 43). In addition to this, IL-33 can also modulate 
Th2 immunity by acting on basophils, eosinophils, and more 
recently described, on newly identified type-2 innate lymphoid 
cells (ILC2), which includes nuocytes, natural helper cells, and 
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innate helper type-2 cells. On these cells, IL-33 promotes IL-5 
and IL-13 secretion (29, 42, 43–45).
Taking all together, there are sufficient indications supporting 
the role of IL-33, either directly or indirectly, in Th2-mediated 
immune responses.
iL-33 on Tregs
In addition to the evidence mentioned above, it is reported that 
IL-33 can also expand and promote Tregs accumulation, among 
other effects, helping to establish tolerance (Figure 1). Different 
animal models support this evidence, from autoimmunity to organ 
transplantation settings.
For the case of autoimmunity, one of the models studied is 
chronic colitis. In this approach, the investigators observed that 
mice treated with exogenous IL-33 manifested a decrease in disease 
symptoms, which was associated to a down-regulation on IFN-γ 
production. This intervention on the cytokine environment led 
to a shift of the T helper response, from Th1 to Th2, reducing 
inflammation in the intestine (30). This work demonstrated the 
capacity of IL-33 to modulate immune responses in this organ, but 
it does not imply necessarily a direct role for Tregs. However, in 
another model of colitis, which is induced by trinitrobenzene sul-
fonic acid (TNBS), the protective role of IL-33 was also observed. 
In this case, the authors evaluated the contribution of Tregs by 
depleting these cells in IL-33-treated diseased animals, obtaining 
a loss in protection compared to non-depleted animals or, in other 
words, Tregs contribute to IL-33-mediated protection (17). One 
could argue that IL-33 may or may not be acting on CD4+ T cells 
because ST2 is expressed by a wide range of cells; nevertheless, a 
Treg-dependent response is seen demonstrating that CD4+ T cells 
can rapidly react (directly or not) to IL-33 stimulation. Supporting 
these findings, Schiering and colleagues described that IL-33 
treatment expands Tregs, increasing Foxp3 and ST2 expression 
in the spleen of mice with ongoing colitis. In this report, IL-33 
treatment did not disturb effector T cell function, but adoptive 
transfer experiments indicated that IL-33 acts on thymic Tregs 
(natural Tregs, nTregs) rendering a stable phenotype by “fixing” 
Foxp3 expression (therefore better suppressors) (31).
Since the expression of ST2 is widely distributed in cells of the 
nervous system, the role of IL-33 signaling has been also studied in 
the EAE model (46). In this experimental setting, IL-33 treatment 
incremented the frequency of Tregs and polarized macrophage 
phenotype toward M2 type in the spinal cord of EAE mice (20).
Furthermore, in atherosclerosis, a typical Th1-type pathology 
in which the frequency and function of Tregs are reduced, it was 
observed that IL-33 treatment of Apo3−/− mice with a high-fat 
diet (model for this disease) prevented the development of ath-
erosclerotic plaques, which is the first symptom of this disease. 
In addition, the authors obtained an increment on IL-4, IL-5, 
and IL-13 production, leading to a decrease in IFN-γ production, 
resulting in a overall switch from Th1 to a protective Th2-type 
response (26). A couple of years later, Wasserman and colleagues 
observed, in the same model, that mice under IL-33 treatment were 
unable to increase the number of cells with regulatory properties 
as wild-type controls (32). They also observed a poor expression 
of ST2 on CD4+ T cells from sick mice, which may be a reason for 
the unresponsiveness to exogenous IL-33 (and the little increase 
of Tregs under this treatment). However, the lack of membrane-
bound ST2 is explained by a mayor concentration of soluble ST2 
(quantified by ELISA), which is a decoy receptor that avoids the 
downstream signaling when IL-33 is bound, preventing response 
to the cytokine (32). Altogether, this evidence suggests that the 
IL-33/ST2 axis is involved in the development of atherosclerosis, 
and proposes that a problem on IL-33 signaling may affect the 
ability of the organism to respond adequately to an unbalance of 
the organism homeostasis.
With respect to the transplantation field, in 2011, Brunner 
and collaborators showed that periodic IL-33 treatment of heart-
transplanted mice resulted in an extended graft survival (33). This 
observation was associated to an increment in CD4+Foxp3+ Tregs 
population, which modulates the response to the graft. Also, the 
CD11b + Gr1int myeloid suppressor-derived cells (MDSCs) were 
augmented, contributing to the acceptance of the graft. Another 
interesting point made in this study is the complete change in 
the cytokine pattern: mice treated with IL-33 showed a decreased 
of IL-17A production, but an increase of IL-13, IL-5, and IL-10 
production of in vitro-cultured, purified graft-infiltrating cells (33). 
With these data, the authors associated the improvement on graft 
survival with a Th2-type response, which favors the induction of 
regulatory cell populations such as Tregs and MDSCs.
In this same topic, our own group has seen an increment in 
CD4+FoxP3+ T cells in mice grafted with semi-allogeneic skin 
transplant and treated with IL-33, which is also related to a better 
state of the graft, a blockade in IFN-γ and IL-17 production and 
increased skin graft survival.
The information above shows that IL-33 participates in the 
induction of tolerance by targeting CD4+ T cells and some APC 
populations, orchestrating an immune response to favor an 
immunoregulatory status of the organism.
The data from all models (autoimmunity and transplantation) 
indicate that IL-33 is involved or may act at different stages of the 
immune response resulting (most likely) in a protective immunity 
for the organism.
iL-33 and CD8+ T Cells
The first role of IL-33 in immunity was linked to the innate-type 
response. But later, several reports showed that IL-33 is able to 
modulate adaptive immunity, mainly by acting directly on CD4+ 
T cells. Until 2009, the role of IL-33 on cytotoxic CD8+ T cells (Tc 
cells) was totally unknown. The first study elucidating a potential 
function of IL-33 on this T cell population was reported by Yang 
and collaborators. His work focused on the contribution of IL-33, 
in a TCR-dependent and -independent fashion, on human and 
murine CD8+ T cell biology in vitro. First, they performed gene 
arrays analysis on murine type-I Tc cells and found that IL-33 was 
one of the genes highly upregulated (34). Since IL-33 affects Th1, 
Th2, and Th17 differentially, the investigators stimulated Tc cells 
under type-1, -2, and -17 conditions, and measured ST2 mRNA. 
The results indicated that ST2 is up-regulated on Tc1 and Tc17 
cells, but IL-4 inhibited ST2 mRNA on Tc2 cells. Interestingly, ST2 
expression on Tc1 seems to be dependent on T-bet, as shown in 
experiments using T-bet KO CD8+ T cells. Conversely, exogenous 
IFN-γ did not alter ST2 expression neither at mRNA nor at the 
protein level (34). Considering that ST2 expression depends on 
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TCR stimulation and T-bet, the authors evaluated the contribution 
of exogenous IL-33 on CD8+ T cell biology. According to the data 
reported above, IL-33 plus IL-12 upregulated IFN-γ, T-bet, and 
Blimp-1 expression on Tc1 cells, downregulating Eomes and IL-7R 
levels (T cell memory-associated molecules), without affecting the 
production of Granzymes or Perforins. Taking together, IL-33 and 
IL-12 enhance effector phenotype on CD8+ T cells (34). As in 
Th1 cells, these results are partially dependent on Gadd45b, a 
protein involved in CD4+ T cell arrest and differentiation (34). 
Another interesting report focused on identifying molecules 
involved in the induction of anti-viral responses. In this work, 
mice were infected with lymphocytic choriomeningitis virus 
(LCMV), and their splenocytes were harvested to analyze gene 
expression changes triggered by LCMV infection. From a panel 
of cytokines and other molecules, IFN-γ and IL-33 were the most 
up-regulated ones, in addition to ST2 (35). IL-33 contribution to 
anti-LCMV response was evaluated infecting Il-33−/−, Il1rl1-Fc, 
and Il1rl1−/−mice, resulting in an impairment of the cytotoxic T 
lymphocyte (CTL)-mediated response. In a similar approach, ST2-
deficient animals infected with murine herpes virus 68 (MHV-
68) presented elevated viral titers, which it was reversed when 
administering exogenous IL-33, suggesting that IL-33 signaling 
is necessary for virus clearance or an effective CTL response. This 
hypothesis was finally proved performing bone marrow chimera 
experiments, in which only wild-type CTLs were responsive to 
LCMV infection versus the ST2-deficient counterpart, given in 
part by a reduced survival and the lack of granzyme B and CD107a 
expression (important molecules involved in cytotoxicity) by the 
deficient cells (35). On the other hand, this experimental approach 
permitted to identify the non-hematopoietic compartment as the 
main source of IL-33 during viral infection. Finally, a very recent 
manuscript describes the role of IL-33 on tumor immunology. 
In this report, the investigators engineered two tumor cell lines 
to over-express (and secrete) IL-33. When injected into mice, 
the IL-33-producing tumor grew less, and the tumor infiltrating 
lymphocytes (TILs) were more abundant than in mice injected 
with control tumor cells. Moreover, when TILs were characterized, 
CD8+ T cells were enriched as in controls, but they displayed 
a more activated and differentiated phenotype given by elevated 
expression of the transcription factors T-bet and Eomes, higher 
IFN-γ secretion, and granzyme B production, demonstrating that 
IL-33 controls CD8+ T cells differentiation and effector function, 
which can be manipulated for anti-tumor therapy (36).
Taken together, the findings described above indicate that not 
only CD4+ T cells get triggered by IL-33 but also CD8+ T cells, 
supporting the idea that IL-33 may modulate T cell-dependent 
functions, which in turn can be reflected on the nature of the 
adaptive immune response.
Future Perspectives
The information above clearly manifests the variety of roles that 
IL-33 exerts in the immune system, considering both innate and 
adaptive types of responses. To manipulate and translate IL-33 
functions to treat disease and restore immune homeostasis or 
tolerance, we need to understand in a more detailed way the 
IL-33 participation during autoimmunity and graft rejection. 
Current studies using animal models show that IL-33 is present 
in the inflammatory response triggered during disease, but 
extensive studies are required using cells and tissue from patients. 
Recapitulating the roles of IL-33 in human settings can open new 
opportunities to design immunological therapies. Of our interest 
is the field of Tregs, where IL-33 positively impacts their biology, 
by mainly expanding or increasing their number in vivo. Is this 
response also observed on human Tregs? Are patient’s Tregs sensi-
tive to IL-33 treatment? Is ST2 expression altered during disease? 
Are IL-33-expanded Tregs able to migrate to inflamed tissue? Many 
questions are still unsolved.
At present, there are some biological therapies that target 
cytokines for treating diseases; thus, a similar approach can be 
used for IL-33. Similar to IL-33, IL-2 therapy was sought to enrich 
for Tregs, since this cytokine acts as a growth factor for T cells. 
In an animal model of diabetes, low dose of IL-2 promoted Treg 
accumulation and function, and favored a switch in cytokine 
milieu given by a reduction on IFN-γ production. Interestingly, 
this low dose of IL-2 did not alter the frequency of other cell types 
(including effector T cells), but Treg number (47). In humans, 
IL-2 administration has also showed benefits, such as an increase 
in functional Treg numbers and a reduction in inflammatory 
signs [GVHD and vasculitis patients (48, 49)]. Alternatively, an 
antibody anti-TNFα was designed to treat RA. This cytokine is 
normally produced in response to local injury; however, it drives 
an exacerbated inflammation producing tissue damage when 
secreted in excess. In RA, TNF-α is present in the synovial fluid 
from patients. At date, there are five biological inhibitors approved 
by the FDA, three of them are monoclonal antibodies (infliximab, 
adalimumab, and golimumab); Etanercept is a fusion protein of 
two TNFR2 receptor extracellular domains plus the Fc fragment 
of human immunoglobulin 1, and Certolizumab is a humanized 
Fab fragment conjugated to polyethylene glycol (50). Although 
the patient life quality improves, they are not an effective treat-
ment due to a loss of effectiveness or severe secondary effects, 
such as higher risk to serious infections or lymphoma (50). Other 
treatments targeting cytokines or their receptors include the 
anti-IL-6R antibody. This approach was developed considering 
the high amounts of IL-6 in the synovial fluid of patients. The 
receptor for this cytokine, IL-6Rα is found in a wide range of 
cells, including T cells, monocytes, activated B cells, neutrophils, 
and hepatocytes (51). Recently, a monoclonal treatment has been 
proved (Tocilizumab), which is capable to block IL-6R, producing 
an improvement in the symptoms. The main problems with this 
therapy are the secondary effects associated with its use. Since 
IL-6 is a very pleiotropic cytokine, many tissues and/or organs get 
affected, including elevated propensity to infections, malignant 
tumors, changes in the blood and lipid profile, hepatic problems, 
and cardiovascular danger (52).
Until date, specificity is the main obstacle for the application of 
this type of approaches, considering that (all) cells expressing or 
producing the cytokine and its receptor could get triggered by the 
administered drug. Therefore, when thinking in the possibility to 
use IL-33 for human treatment, we need to be specific regarding its 
target, because of its wide effects on cell types and, consequently, in 
the microenvironment. This phenomenon is related to the signal-
ing pathways triggered during the encounter between the cytokine 
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and its receptor. For this reason, a better knowledge on IL-33 
signaling and its interaction with others molecules are really 
necessary. Based in the different responses observed in a same 
animal model for diseases, we could think that dosage, timing, 
microenvironment, and state of the disease are key variables that 
may affect the final outcome of IL-33 treatment; thus, determin-
ing when these factors are aligned to favor a polarization to Tregs 
(for autoimmunity or block graft rejection) would be useful to 
act positively in the patient.
Lastly, the administration method is not less important. For 
delivery of sensitive molecules, such as cytokines, an interest-
ing solution is the use of novel technologies. Nanomedicine 
supports the control, repair, and improvement of the human 
biological system working from the molecular level, and it has 
been proposed as a possible solution for the controlled release 
of a desired molecule. It consists in establishing nanostructures 
to carry a drug to an affected area, encapsulating, and releasing 
it at its destination under specific conditions (53). This dynamic 
mechanism is called nanotherapy and it is characterized by 
several benefits including improvement in disease detection 
and good rate of absorption and treatment of patients. Among 
the nanostructures designed, we can find nanoparticles, nano-
capsules, dendrimers, liposomes, micelles, nanotubes, and 
microgeles, each of one with characteristic properties. Applying 
the above to IL-33 may be a great opportunity to create a therapy 
through specific targeting leading to an effective cure to restore 
immune tolerance (54).
In summary, there is still a lot to know and understand 
about IL-33; however, the results shown to date gives us positive 
expectations on a new therapy involving this cytokine.
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